Bank of America
ACTU

Bank of America’s Actuate Therapeutics ACTU Stock Holding History

Bank of America’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.2K Buy
11,034
+1,973
+22% +$8.17K ﹤0.01% 5635
2025
Q4 		$55.5K Buy
9,061
+4,189
+86% +$28.8K ﹤0.01% 5814
2025
Q3 		$32.6K Sell
4,872
-10,420
-68% -$75.5K ﹤0.01% 6953
2025
Q2 		$93.4K Buy
15,292
+15,267
+61,068% +$133K ﹤0.01% 6548
2025
Q1 		$169 Buy
25
+1
+4% +$8 ﹤0.01% 7729
2024
Q4 		$191 Buy
24
+1
+4% +$8 ﹤0.01% 7596
2024
Q3 		$171 Buy
+23
New +$182 ﹤0.01% 7607

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America's ACTU Position: Q1 2026 in Review

Bank of America increased its Actuate Therapeutics (ACTU) stake by 22% in Q1 2026, buying an estimated $8.17K and bringing the position to 11,034 shares worth $30.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5635.

Bank of America first reported a position in ACTU in Q3 2024 and has held it in 7 quarters since. The position peaked at $93.4K in Q2 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Bank of America held 11,034 shares of Actuate Therapeutics worth $30.2K as of Q1 2026.
  • Bank of America bought 1,973 Actuate Therapeutics shares in Q1 2026, an estimated $8.17K.
  • Actuate Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5635 holding.
  • Bank of America first reported a position in Actuate Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Bank of America's Actuate Therapeutics position peaked at $93.4K in Q2 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.